The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 39% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 125%. Our forward projection puts the odds of a 10% gain over the next month near 41%. The street (2 analysts) rates it buy, with a mean price target of $14.
Silvercorp Metals Inc. SVM
Clears both ethical standards
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
read at $8.92
Silvercorp Metals Inc. holds its Distribution at $8.92.
- PHPhase · the trend structure carries the Distribution label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 43 days |
| Price | $8.92 |
| Valuation | N/A trailing · 5.33 forward price to earnings |
| Values screen | PASS |
| Beta | 1.97 |
The opportunity · what the numbers say it is worth
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
| Revenue growth | 96.20% |
| Profit margin | -2.27% |
| Debt to equity | 10.71 |
| Analyst consensus | Strong Buy · 2 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✓ PASSES
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is just 4.4% of its assets, well under the one-third ceiling — it does not run on borrowed money. Pass
- Interest-bearing cash Cash held in interest-bearing accounts and securities is 17.5% of assets, under the one-third limit. Pass
- Receivables Money owed to the company is 0.0% of assets, under the 49% limit. Pass
- Revenue purity Only 0.0% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Cheap miners at five times earnings often trap value
Picture a silver miner posting 96% revenue growth while still losing money on every ounce sold. Silvercorp shows exactly that mix, with a forward multiple of 5.3 times earnings and a claimed 35% margin of safety to fair value. Yet the business carries a weak moat, returns on equity of just 3%, and a negative profit margin, all inside an industry where earnings peak and trough with metal prices.
The low multiple and analyst target near 14 dollars make the shares appear undervalued on paper. Ethical screens clear it without issue. In cyclical metals, however, that combination usually signals peak earnings rather than a bargain, and the numbers here offer little evidence the next downswing has been priced in.
High revenue growth can vanish quickly when prices fall, and thin returns leave little cushion. The absence of any durable advantage means the company will likely compete away any windfall the moment conditions normalise. Analysis, not advice.
| Forward P/E | 5.3x cheap for a company growing this fast |
| Revenue growth | 96.2% growing very fast |
| Profit margin | -2.3% currently unprofitable |
| Return on equity | 3.4% a modest return on shareholder capital |
| Debt to equity | 0.11 minimal debt — a conservative balance sheet |
| Current ratio | 3.58 comfortably covers its short-term bills |
| Beta | 1.97 much more volatile than the market |
| Market cap | $2.0B |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in SVM's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
SVM trades on NYSE American. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
The insider ledger · Form 4 filings, as filed
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-21 | Liu (Yikang) | Director of Issuer | 2,334 | $8,661 | |
| 2026-04-21 | Liu (Yikang) | Director of Issuer | 4,333 | $13,986 | |
| 2026-04-21 | Liu (Yikang) | Director of Issuer | 7,334 | $87,281 | |
| 2026-04-15 | Lekich (Peter) | Senior Officer of Issuer | 7,499 | · | |
| 2026-04-14 | Cai (Hongyu) | Director of Issuer | 8,333 | · | |
| 2026-04-14 | Lekich (Peter) | Senior Officer of Issuer | 2,050 | $25,317 | |
| 2026-04-14 | Liu (Yikang) | Director of Issuer | 12,500 | · | |
| 2026-04-14 | Wang (Winnie) | Senior Officer of Issuer | 834 | · | |
| 2026-04-09 | Katusa (Marina A.) | Director of Issuer | 12,500 | · | |
| 2026-03-10 | Lekich (Peter) | Senior Officer of Issuer | 4,200 | $52,117 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $14.73 | -35.0% | $0.01 | $651 | -34.9% |
| 2 months | $11.49 | -16.6% | $0.01 | $835 | -16.5% |
| 3 months | $11.53 | -16.9% | $0.01 | $832 | -16.8% |
| 6 months | $8.53 | +12.3% | $0.01 | $1,125 | +12.5% |
| 1 year | $4.26 | +125.1% | $0.01 | $2,254 | +125.4% |
| 2 years | $3.58 | +167.5% | $0.04 | $2,686 | +168.6% |
| 3 years | $2.99 | +220.5% | $0.07 | $3,227 | +222.7% |
| 5 years | $6.13 | +56.2% | $0.12 | $1,581 | +58.1% |
Historical returns from market close data. Past performance does not guarantee future results.